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Abstract
EUCAST breakpoint criteria are being adopted by automatic antimicrobial susceptibility testing systems. The accuracy of the Phoenix
Automated System in combination with 2012 EUCAST breakpoints against recent clinical isolates was evaluated. A total of 697 isolates
(349 Enterobacteriaceae, 113 Pseudomonas spp., 25 Acinetobacter baumannii, 11 Stenotrophomonas maltophilia, 95 Staphylococcus aureus, 6
coagulase negative staphylococci, 77 enterococci and 21 Streptococcus pneumoniae) with deﬁned resistance phenotypes and well-charac-
terized resistance mechanisms recovered in Spain (n = 343) and Italy (n = 354) were tested. Comparator antimicrobial susceptibility
testing data were obtained following CLSI guidelines. Experimental agreement (EA), deﬁned as MIC agreement ±1 log2 dilution, category
agreement (CA) and relative discrepancies (minor (mD), major (MD) and very major discrepancies (VMD)) were determined. The over-
all EA and CA for all organism-antimicrobial agent combinations (n = 6.294) were 97.3% and 95.2%, respectively. mD, MD and VMD
were 4.7%, 1.3% and 2.7%, all of them in agreement with the ISO (ISO20776-2:2007) acceptance criteria for assessment of susceptibility
testing devices. VMD were mainly observed in amoxicillin-clavulanate and cefuroxime in Enterobacteriaceae and gentamicin in Pseudomo-
nas aeruginosa, whereas MD were mainly observed in amoxicillin-clavulante in Enterobacteriaceae. mD were mainly observed in Entero-
bacteriaceae but distributed in different antimicrobials. For S. aureus and enterococci relative discrepancies were low. The Phoenix
system showed accuracy assessment in accordance with the ISO standards when using EUCAST breakpoints. Inclusion of EUCAST cri-
teria in automatic antimicrobial susceptibility testing systems will facilitate the implementation of EUCAST breakpoints in clinical micro-
biology laboratories.
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Introduction
Accuracy determination of antimicrobial susceptibility testing
(AST) in clinical laboratories is essential not only for guiding
the antimicrobial treatment in a speciﬁc patient but also from
a general perspective for compiling data for antimicrobial
guidance [1,2]. The European Committee on Antimicrobial
Susceptibility Testing (EUCAST), in agreement with the
European Medicines Agency (EMA) and the European Centre
for Disease Prevention and Control (ECDC), has deﬁned
clinical breakpoints to allow European microbiology laborato-
ries to use harmonized criteria for the interpretation of AST
results (http://www.eucast.org). These criteria are being
adopted by a number of European Union (EU) member
states and it is likely that in a short time period they will be
used by all EU countries. Automatic diagnostic systems cur-
rently present in the market and commonly used for AST in
clinical laboratories will therefore have to incorporate these
criteria in their instruments to meet the needs of European
microbiology laboratories.
ª2012 The Authors
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The PhoenixTM Automated Microbiology System (BD
Diagnostics, Sparks, MD, USA) is designed for the rapid bac-
terial identiﬁcation at the species level and determination of
AST of clinically signiﬁcant human bacterial pathogens [3].
Performance of this system has been previously evaluated
using the CLSI breakpoints but not the EUCAST ones [4–
11]. These evaluations are commonly established using Food
and Drug Administration (FDA) criteria but not with those
from the International Standard Organization [12,13]. In
addition, the Phoenix system has demonstrated accuracy in
identiﬁcation of isolates with resistance mechanisms, includ-
ing extended-spectrum b-lactamases (ESBL), acquired AmpC
b-lactamases, certain carbapenemases in gram-negatives,
PBP2a in Staphylococcus aureus and vancomycin resistance
determinants in Enterococcus [8,14,15]. The objective of this
work was to evaluate the performance of the Phoenix sys-
tem for the determination of bacterial AST using the EU-
CAST standards in two different centres. A library of
selected isolates with well-deﬁned phenotypes and well-char-
acterized resistance mechanisms was used.
Materials and Methods
Bacterial isolates
A total of 697 isolates were tested, 343 from laboratory A
(Ramo´n y Cajal University Hospital, Madrid, Spain) and 354
from laboratory B (University of Siena, Siena, Italy). Both of
these laboratories selected clinical isolates with well-deﬁned
resistance phenotypes obtained from routine clinical sample
processing (150 from laboratory A and 175 from laboratory
B) during 2009 and isolates with well-characterized resis-
tance mechanisms (193 from laboratory A and 179 from lab-
oratory B). Details of the organisms tested are shown in
Table 1. Resistance mechanisms were characterized by
molecular methods, including PCR and sequencing, described
elsewhere.
Antimicrobial susceptibility testing
The BD PhoenixTM (Phoenix) Automated Microbiology Sys-
tem (Becton-Dickinson Diagnostic Systems, Sparks, MD,
USA), equipped with software suitable for interpretation of
AST results using EUCAST breakpoints (document V1.3,
2011, http://www.eucast.org), was used for performing the
antimicrobial susceptibility testing. The panels selected to
perform the evaluation were NMIC/ID-76 for gram-nega-
tives, PMIC/ID-67 for staphylococci and enterococci, and
SMIC/ID-9 for Streptococcus pneumoniae. These panels, intro-
duced into the market in 2009, contained a range of doubling
dilutions of different antimicrobials to cover the breakpoints T
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recommended by EUCAST (document V1.3, 2011, http://
www.eucast.org/). Selected antibiotics for each group of
microorganisms are shown in Table 1.
Isolates to be tested were plated at least once on sheep
blood Columbia agar and incubated overnight at 35–37C.
An initial suspension was made in Phoenix-ID broth and
adjusted to a density corresponding to MacFarland 0.5.
Twenty-ﬁve microlitres of the initial inoculum were then
transferred into 8 mL Phoenix AST broth. This ﬁnal suspen-
sion was then poured into the panel, which was then placed
in the instrument.
MIC results in recent clinical isolates with well-deﬁned
resistance phenotypes and isolates with well-characterized
resistance mechanisms were previously obtained following
CLSI criteria for each bacterial species [16]. Mueller-Hinton
broth, inoculum of 5 · 105 CFU/mL and incubation period of
18 h were used.
Data evaluation
To assess the performance of the Phoenix system, essential
agreement (EA), category agreement (CA) and relative dis-
crepancies were determined considering different antimicro-
bial agents for each microorganism (Table 1).
Essential agreement was deﬁned when the MICs obtained
with the Phoenix system and by the CLSI method were iden-
tical or ±1 log2 dilution. CA was deﬁned as clinical interpre-
tive category agreement between the Phoenix system and
the standard CLSI method after applying the EUCAST break-
points published in 2012 (document V2.0, 2012, http://
www.eucast.org/). MIC results previously obtained in recent
clinical isolates with well-deﬁned resistance phenotypes and
in isolates with well-characterized resistance mechanisms
with the CLSI microdilution method were re-interpreted for
the susceptible, intermediate and resistant categories using
the 2012 EUCAST breakpoints. In addition, relative discrep-
ancies were determined for each antimicrobial-organism
combination. Discrepancies were classiﬁed as very major dis-
crepancy (VMD) when the MIC obtained with the Phoenix
system was categorized as susceptible and that obtained with
the standard method was categorized as resistant. A major
discrepancy (MD) occurred when the comparator system
result (Phoenix) was resistant and that obtained with the
standard method was susceptible. A minor discrepancy (mD)
occurred when the Phoenix system result was resistant or
susceptible and the standard method result intermediate, and
also when the Phoenix system result was intermediate and
the standard method result susceptible or resistant. mD
were not recorded when the intermediate category was not
recognized by EUCAST. When computing the discrepancy
errors, the number of resistant isolates, the number of
susceptible isolates and the total number of tests were used
as denominators for VMD, MD and mD, respectively. In the
case of VMD or MD, we tried to resolve discrepancies by
retesting the isolate in duplicate using both Phoenix and
Etest or by using the CLSI microdilution method. Unsolved
discrepancies were maintained in the database for calculation
of the discrepancies.
Acceptance criteria for accuracy assessment were those
deﬁned by the ISO standards: EA ‡90%, VMD £3% and MD
£3% [13].
Quality control (QC) testing
For QC purposes, six ATCC reference isolates were tested
in each run: S. aureus ATCC 29213, Enterococcus faecalis
ATCC 29212, Streptococcus pneumoniae ATCC 49619, Escher-
ichia coli ATCC 25922, Klebsiella pneumoniae ATCC 700603
and Pseudomonas aeruginosa ATCC 27853. These isolates
were used as daily quality controls at both sites for the
entire duration of the study. If the results for one antimicro-
bial were not within the expected range, all results for the
speciﬁc drug obtained during that study day were excluded
from the dataset and repeated upon resolution of the issue.
Results
A total of 6294 organism-antimicrobial agent combinations
were analysed. The studied organisms include 349 isolates of
the family Enterobacteriaceae, 113 Pseudomonas spp., 25 Aci-
netobacter baumannii, 11 Stenotrophomonas maltophilia, 95
S. aureus, 6 coagulase negative staphylococci, 77 enterococci
and 21 S. pneumoniae (Table 1). Detailed results for major
groups of organisms and antibiotics can be observed in
Tables 2–5. The overall EA in MIC (±1 log2 dilution) for all
the organism-antimicrobial agent combinations was 97.3%;
1.7% (n = 105) of the organism-antimicrobial combination
results with the Phoenix system were 2 or more dilutions
lower than the standard values and 1.0% (n = 67) of the
organism-antimicrobial combination results were 2 or more
dilutions higher than the standard values. In both cases, the
majority of discrepancies were due to ESBL- and carbape-
nemase-producing isolates (see below).
The overall CA of the Phoenix system was 95.2%, ranging
from 92.9% in Pseudomonas spp. to 100.0% in S. maltophilia.
Overall mD, MD and VMD were 4.7%, 1.3% and 2.7%,
respectively, all of them in agreement with the ISO accep-
tance criteria for accuracy assessment of susceptibility test
devices [13]. When considering all resistant test results
(n = 2184) for relevant bacterial groups (Tables 2–5), the VMD
(n = 62) were mainly concentrated in amoxicillin-clavulanate
E454 Clinical Microbiology and Infection, Volume 18 Number 11, November 2012 CMI
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TABLE 2. Performance of the Phoenix automatic system and EUCAST breakpoints in Enterobacteriaceae isolates
Antimicrobial
agentsa No. of tests
No. of organism-antimi-
crobial agent combina-
tions categorized as
Essential
agreement (%)
Category
agreement (%)
Discrepanciesb
Resistant Susceptible mD (%) MD (%) VMD (%)
AXC 349 235 114 328 (94.0) 318 (91.1) –c 23 (20.2) 8 (3.4)
TZP 349 110 221 345 (98.8) 332 (95.1) 14 (4) 3 (1.4) 0 (0.0)
CXM 197 155 42 187 (94.9) 184 (93.4) –c 2 (4.8) 11 (7.1)
CTX 349 249 100 340 (97.4) 344 (98.5) 4 (1.1) 0 (0.0) 1 (0.4)
CAZ 349 196 119 342 (98.0) 328 (93.9) 20 (5.7) 0 (0.0) 1 (0.5)
IPM 349 3 305 337 (96.6) 330 (94.6) 19 (5.4) 0 (0.0) 0 (0.0)
MEM 348 7 320 336 (96.5) 332 (95.4) 16 (4.6) 0 (0.0) 0 (0.0)
ETP 152 23 129 152 (100.0) 151 (99.3) 1 (0.7) 0 (0.0) 0 (0.0)
CIP 349 160 164 327 (93.7) 321 (92) 27 (7.7) 0 (0.0) 1 (0.6)
GM 349 101 224 345 (98.8) 322 (92.3) 25 (7.2) 1 (0.4) 1 (1.0)
NN 197 75 116 194 (98.5) 185 (93.9) 11 (5.6) 0 (0.0) 1 (1.3)
SXT 197 72 122 194 (98.5) 191 (96.9) 5 (2.5) 0 (0.0) 1 (1.4)
Total 3534 1386 1976 3427 (97.0) 3338 (94.5) 142 (4.7) 29 (1.4) 25 (1.8)
aAbbreviations for antibiotics, see Table 1.
bmD, minor discrepancies; MD, major discrepancies; VMD, very major discrepancies.
cNo intermediate category has been deﬁned for these antibiotics.
TABLE 3. Performance of the Phoenix automatic system and EUCAST breakpoints in Pseudomonas aeruginosa isolates
Antimicrobial
agentsa No. of tests
No. of organism-antimi-
crobial agent combina-
tions categorized as
Essential
agreement (%) Category agreement (%)
Discrepanciesb
Resistant Susceptible mD (%) MD (%) VMD (%)
ATM 56 15 9 46 (82.1) 40 (71.4) 16 (28.6) 0 (0.0) 0 (0.0)
TZP 110 50 60 110 (100.0) 105 (95.5) –c 3 (5.0) 2 (4.0)
CAZ 110 51 59 104 (94.5) 108 (98.2) –c 1 (1.7) 1 (2.0)
IPM 110 47 59 108 (98.2) 102 (92.7) 7 (6.4) 1 (1.7) 0 (0.0)
MEM 110 46 53 101 (91.8) 97 (88.2) 13 (11.8) 0 (0.0) 0 (0.0)
CIP 110 61 46 108 (98.2) 106 (96.4) 4 (3.6) 0 (0.0) 0 (0.0)
GM 110 63 47 105 (95.4) 94 (85.5) –c 0 (0.0) 16 (25.4)
NN 50 12 38 50 (100.0) 49 (98.0) –c 0 (0.0) 1 (8.3)
CL 109 0 109 108 (99.1) 109 (100) –c 0 (0.0) 0 (0,0)
Total 875 345 480 840 (96.0) 810 (92.5) 40 (10.4) 5 (1.0) 20 (5.7)
aAbbreviations for antibiotics, see Table 1.
bmD, minor discrepancies; MD, major discrepancies; VMD, very major discrepancies.
cNo intermediate category has been deﬁned for these antibiotics.
TABLE 4. Performance of the Phoenix automatic system and EUCAST breakpoints in Staphylococcus aureus
Antimicrobial
agentsa No. of tests
No. of organism-antimi-
crobial agent combinations
categorized as
Essential
agreement (%)
Category
agreement (%)
Discrepanciesb
Resistant Susceptible mD (%) MD (%) VMD (%)
FOX 45 25 20 41 (91.1) 43 (95.6) – 2 (10.0) 0 (0.0)
CIP 42 24 18 42 (100.0) 42 (100.0) – 0 (0.0) 0 (0.0)
CLI 95 16 79 95 (100.0) 95 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
DAP 92 4 88 92 (100.0) 89 (96.7) –c 1 (1.1) 2 (50.0)
EM 95 46 46 92 (96.8) 92 (96.8) 3 (3.1) 0 (0.0) 0 (0.0)
GM 95 27 68 94 (98.9) 93 (97.9) –c 0 (0.0) 2 (7.4)
LZD 95 0 95 94 (98.9) 95 (100.0) –c 0 (0.0) 0 (0.0)
MXF 42 23 17 41 (97.6) 41 (97.6) 1 (2.4) 0 (0.0) 0 (0.0)
OXA 95 47 48 92 (96.8) 91 (95.8) –c 4 (8.3) 0 (0.0)
PEN 95 88 7 94 (98.9) 95 (100.0) –c 0 (0.0) 0 (0.0)
TEC 45 13 32 45 (100.0) 41 (91.1) –c 2 (6.2) 2 (15.4)
TET 44 12 31 43 (97.7) 43 (97.7) 0 (0.0) 0 (0.0) 1 (8.3)
VAN 95 0 95 93 (97.9) 95 (100.0) –c 0 (0.0) 0 (0.0)
FUS 50 3 47 50 (100.0) 50 (100.0) –c 0 (0.0) 0 (0.0)
Total 1025 328 691 1008 (98.3) 1005 (98.0) 4 (1.4) 9 (1.3) 7 (2.1)
aAbbreviations for antibiotics, see Table 1.
bmD, minor discrepancies; MD, major discrepancies; VMD, very major discrepancies.
cNo intermediate category has been deﬁned for these antibiotics.
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(n = 8) and cefuroxime (n = 11) in Enterobacteriaceae and
gentamicin (n = 16) in P. aeruginosa. The MD (n = 44) were
mainly concentrated in amoxicillin-clavulanate (n = 23) in
Enterobacteriaceae. Most of the mD were observed in Entero-
bacteriaceae but distributed in different antimicrobials
(Table 2).
When considering the Enterobacteriaceae isolates, EA val-
ues were all higher than 95%, except for ciproﬂoxacin
(93.7%), amoxicillin-clavulanate (94.0%) and cefuroxime
(94.9%) (Table 2). In this group of organisms, CA ranged
from 91.1% for amoxicillin-clavulanate to 99.3% for ertape-
nem. The amoxicillin-clavulanate CA value was reﬂected in
error discrepancies as this combination had the highest MD
values (20.2%). VMD (overall n = 25, 1.8%) were concen-
trated in amoxicillin-clavulate (n = 8, 3.4%) and cefuroxime
(n = 11, 7.1%). These discrepancies were mainly due to
ESBL-producing isolates; 17/23 (7 E. coli and 10 K. pneumo-
niae) MD as well as 7/8 (4 E. coli and 3 K. pneumoniae) VMD
were observed in isolates with well-characterized ESBLs
(data not shown in Tables).
In P. aeruginosa isolates (Table 3), EA values were also
higher than 95%, except for aztreonam (82.1%), ceftazidime
(94.5%) and meropenem (91.8%). The CA ranged from
71.4% for aztreonam to 100.0% for colistin. Discrepancies
were unusual but concentrated in VMD for gentamicin
(n = 16, 25.4%) and mD for aztreonam (n = 16, 28.6%) and
meropenem (n = 13, 11.8%). These discrepancies mainly
occurred in carbapenemase-producing isolates. Regarding
VMD for gentamicin, 6/16 were recorded with P. aruginosa
isolates with well-characterized resistance mechanisms, and 5
were VIM positive (in all ﬁve cases, the Phoenix system gave
-1 MIC result, 4 instead 8 mg/L). Moreover, 10/16 mD for
aztreonam were obtained with VIM- or IMP-producing P. aru-
ginosa isolates and mD for meropenem, nine of them with
isolates with well-characterized resistance mechanisms (six
VIM- or IMP- and three PER-producing isolates) (data not
shown in Tables).
In S. aureus (Table 4), CA was always higher than 95%,
including oxacillin. Moreover, EA always exceeded 96%, with
the exception of cefoxitin (91.1%). Only 15 discrepancies
were recorded when analysing the relative discrepancies and
four (8.3%) of them were MD for oxacillin. In enterococci
(Table 5) and with the exception of gentamicin (94.8%), CA
was higher than 95%. Only 11 discrepancies were recorded
in enterococci, nine (14.8%) of them were VMD for gentami-
cin.
Discussion
Antimicrobial susceptibility testing interpretation in Europe
has been traditionally driven by local committees or by the
CLSI standards but nowadays most European countries are
moving to EUCAST breakpoints. The EUCAST committee
was formed in 1996 and reorganized in 2001 with the aim of
harmonization of existing breakpoints [17]. The harmoniza-
tion process was ﬁnished in 2009 and EUCAST became the
breakpoint committee of EMA and ECDC. EUCAST break-
points are being introduced into devices for automated sus-
ceptibility testing but with some limitations, depending on
the system (http://www.eucast.org).
The Phoenix automatic system has included adequate
antimicrobial concentrations in most of its panels to imple-
ment the EUCAST breakpoints as well as deﬁnitions of sus-
ceptible and resistant clinical categories (http://www.bd.com/
resource.aspx?IDX=10841, last accession June 25, 2012).
The Phoenix system suppresses from the ﬁnal report the
drugs with MIC values interpreted with a dash (‘-’) (suscep-
tibility testing is not recommended as the species is a poor
target for therapy with the drug) as well as with the acro-
nym ‘IE’, which indicates that there is insufﬁcient evidence
that the species in question is a good target for therapy
with the drug. In both cases, the MIC remains visible at the
laboratory level.
TABLE 5. Performance of the Phoenix automatic system and EUCAST breakpoints in enterococci
Antimicrobial
agentsa No. of tests
No. of organism-antimi-
crobial agent combinations
categorized as
Essential
agreement (%)
Category
agreement (%) mD (%) MD (%) VMD (%)Resistant Susceptible
GM 77 61 16 69 (89.6) 68 (94.8) –c 0 (0.0) 9 (14.8)
LZD 77 0 77 74 (96.1) 77 (100.0) –c 0 (0.0) 0 (0.0)
AM 76 23 52 76 (100.0) 76 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
TEC 77 14 63 76 (98.7) 76 (98.7) –c 1 (1.6) 0 (0.0)
VAN 77 26 51 77 (100.0) 76 (97.4) 0 (0.0) 0 (0.0) 1 (3.8)
NIT 29 1 28 29 (100.0) 29 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Total 413 125 287 401 (97.1) 402 (97.3) 0 (0.0) 1 (0.3) 10 (8.0)
aAbbreviations for antibiotics, see Table .
bmD, minor discrepancies; MD, major discrepancies; VMD, very major discrepancies.
cNo intermediate category has been deﬁned for these antibiotics.
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Different studies of the accuracy of different automatic
susceptibility tests have been published, most of them using
CLSI breakpoints. In our study, we evaluate the accuracy of
the Phoenix system with current EUCAST breakpoints (doc-
ument 2.0, http://www.eucast.org) using a panel of isolates
representing relevant resistance mechanisms such as ESBL-
and carbapenemase-producing isolates, as well as methicillin
resistance in S. aureus or vancomycin resistance in entero-
cocci. To our knowledge, this is the ﬁrst time that a suscep-
tibility testing device using EUCAST breakpoints has been
evaluated. Acceptance criteria for accuracy assessment were
in agreement not only with those described by the ISO stan-
dard [13] but also with those required by the FDA in the
USA [12]. The Phoenix system was previously evaluated
using CLSI breakpoints and different panels of organisms,
including speciﬁc resistance mechanisms [4–11,14,15].
In our evaluation, overall MD and VMD discrepancies
were below 3%, with a ﬁgure of 4.7% for mD. In general, the
number of discrepancies in gram-negative organisms was
higher than that found in gram-positive bacteria. This can be
associated with the complexity of the resistance mechanism
in the selected gram-negative isolates for this evaluation,
most of them having an enzymatic resistance mechanism
affecting b-lactam antibiotics. When discrepancies were spe-
ciﬁcally analysed, amoxicillin-clavulanate in Enterobacteria-
ceae was responsible for a majority of them, with a high
proportion of MD and VMD discrepancies. AST of b-lactam-
b-lactamase inhibitor combinations has been previously
reported as problematic in certain automatic systems related
to the instability of the b-lactamase inhibitors [18,19]. The
effect of speciﬁc enzymatic resistance mechanisms that can
be present in the microorganisms, including ESBL, and poten-
tial ﬂuctuation of ±1 log2 MIC value in the absence of an
intermediate EUCAST clinical category in Enterobacteria-
ceae, could be responsible for these discrepancies. Most of
the discrepant isolates were within the Spanish isolates.
Unlike amoxicillin-clavulanate, carbapenems showed mD but
not MD or VMD. Heteroresistance and variable expression
of the carbapenemase-mediated carbapenem resistance
mechanism can be responsible for these discrepancies [20].
Gentamicin discrepancies in Enterobacteriaceae and P. aeru-
ginosa with a high proportion of mD and VMD, respectively,
are also of note. The former can be related to a narrow
range of concentrations in the EUCAST intermediate cate-
gory and the latter to the absence of a EUCAST intermedi-
ate category for this antibiotic. An antibiotic with a high
proportion of discrepancies is ciproﬂoxacin. They were
mainly concentrated in Enterobacteriaceae (nearly all mD).
The inclusion of a single antimicrobial concentration in the
EUCAST intermediate category for ciproﬂoxacin accounts
for these mD.
An interesting feature of the Phoenix system is its excel-
lent accuracy in gram-positive isolates. The studied collection
of S. aureus included a high proportion of methicillin-resistant
isolates and also isolates with decreased susceptibility to gly-
copeptides. Despite this fact, CA for these antibiotics was
high and discrepancies not noticeable. This was also the case
for glycopeptides and enterococci. The robustness of the
Phoenix system for AST of these organisms has been previ-
ously described [4,8,15].
In summary, we have evaluated the accuracy of the Phoe-
nix AST system when using EUCAST breakpoints. Despite
the inclusion of a panel of isolates with complex resistance
mechanisms from two different laboratories, EA, CA and dis-
crepancy rates were in agreement with the acceptance crite-
ria established by the ISO standard [12]. Interpretive
category discrepancies observed in speciﬁc organism-antimi-
crobial combinations were mainly due to particular break-
points, such as those for amoxicillin-clavulanate, gentamicin
or ciproﬂoxacin, or the heterogeneous expression of resis-
tant mechanisms such as metallo b-lactamases affecting car-
bapenems. Inclusion of EUCAST criteria in automatic
systems for susceptibility testing will facilitate the implemen-
tation of EUCAST breakpoints in clinical microbiology labo-
ratories.
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